Cheap Semaglutide: How Pricing Actually Works

Which product and dose a quote covers

Ozempic has no weight-loss indication; its label covers glycemic control in type 2 diabetes, cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, and kidney outcomes in adults with type 2 diabetes and chronic kidney disease [6]. The weight-management indication belongs to Wegovy, also sold as once-daily tablets approved 22 December 2025 for adults [3][5]. Wegovy injection runs 0.25 mg for weeks 1 to 4, then 0.5, 1 and 1.7 mg in four-week steps [5]. From week 17, the recommended adult weight-reduction maintenance dose is 2.4 mg weekly; 1.7 mg weekly is also an option, and some adults who tolerate 2.4 mg for at least four weeks may increase to a maximum of 7.2 mg weekly [5]. To compare two monthly quotes on equal terms, check the product (Wegovy injection, Wegovy tablets, Ozempic or compounded), the form, the dose step, and whether the quoted charge is for the starting dose or the maintenance dose; the label schedule increases before maintenance [5].

What changed in 2025

On 21 February 2025 FDA announced it would stop tolerating the compounding of semaglutide injection that had depended on temporary flexibility, and set end dates for that flexibility [1]. The grace period for state-licensed pharmacies and physicians ended after a court denied the compounders' injunction request on 24 April 2025; for outsourcing facilities FDA said it would not act until 22 May 2025 [1]. A pharmacy may now compound only for an individual patient on a prescription, and a product that is essentially a copy of an approved drug is allowed only if made rarely (FDA does not intend to act against four or fewer such prescriptions per calendar month) or if the prescriber documents a significant difference [1]. Adding vitamin B12 may not change that: FDA says such a product may still be essentially a copy if the route is the same and the amounts of semaglutide and B12 are each within 10% of their respective commercial products [1]. On 30 April 2026 FDA proposed excluding semaglutide from the outsourcing bulks list; comments were due 29 June 2026 and no final decision has been made [7].

What FDA flags in a cheap offer

Compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before marketing [8]. As of 31 May 2026 FDA had received 990 adverse event reports for compounded semaglutide and says this likely undercounts; it also reports dosing errors and states that semaglutide sodium and acetate salts are different active ingredients with no lawful basis for compounding that it is aware of [8]. FDA lists deep discounts or prices that seem too good to be true, no screening and prescription by a licensed doctor, no licensed doctor available afterward, and misspelled labels or damaged packaging among warning signs [8]. A low price by itself does not show whether the product is FDA approved or compounded.

HealthRX.com offers compounded semaglutide by prescription.